EBRCZ EBR Systems, Inc.
Surgical & Medical Instruments & Apparatus · OTC · SEC CIK 1347123 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-45.6%
TTM EPS YoY83.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin11.4%
Operating margin-737.5%
Net margin-774.5%
FCF margin-919.0%
EBITDA margin-726.4%
Returns
ROE-112.9%
ROA-51.7%
ROIC (approx.)-57.8%
Asset turnover0.07x
Leverage & solvency
Liabilities / assets47.8%
Debt / equity0.54x
Current ratio2.11x
Interest coverage-11.50x
Cash quality & payout
Operating cash flow / net income1.07x
Accruals ratio3.6%
Payout ratio—
Capex / revenue91.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $2.49M | $2.64M | $2.36M | $935,203 | $512,000 | $170,000 | — | — |
| Cost of revenue | $2.24M | $2.29M | $2.18M | $753,354 | $288,000 | $85,000 | — | — |
| Gross profit | $249,000 | $343,000 | $184,000 | $181,849 | $224,000 | $85,000 | — | — |
| R&D expense | $6.70M | $6.62M | $6.42M | $6.33M | $6.24M | $5.95M | $5.42M | $6.89M |
| SG&A expense | $9.80M | $10.12M | $9.94M | $7.15M | $5.86M | $5.26M | $4.36M | $2.93M |
| Operating income | -$16.25M | -$16.40M | -$16.17M | -$13.29M | -$11.88M | -$11.13M | -$9.78M | -$9.83M |
| Interest expense | $1.36M | $1.33M | $1.32M | $1.39M | $1.43M | $1.43M | $1.40M | $1.47M |
| Pretax income | -$16.64M | -$17.45M | -$17.07M | -$14.05M | -$12.19M | -$11.97M | -$10.55M | -$10.10M |
| Income tax | — | — | — | $2,000 | $0 | $0 | $0 | $1,535 |
| Net income | -$16.64M | -$17.45M | -$17.07M | -$14.05M | -$12.19M | -$11.97M | -$10.55M | -$10.10M |
| EBITDA | -$15.85M | -$16.10M | -$16.05M | -$13.18M | -$11.78M | -$11.03M | -$9.70M | -$9.74M |
| EPS (basic) | -0.21 | -0.35 | -0.38 | — | -0.27 | -0.30 | -0.28 | — |
| EPS (diluted) | -0.21 | -0.35 | -0.38 | — | -0.27 | -0.30 | -0.28 | — |
| Weighted avg. shares (diluted) | 79.04M | 49.24M | 45.04M | — | 44.97M | 39.59M | 37.25M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $13.98M | $59.35M | $6.56M | $5.79M | $15.25M | $47.60M | $11.50M | $6.92M |
| Short-term investments | $71.43M | $26.59M | $23.32M | $47.40M | $55.72M | $36.70M | $38.97M | $53.75M |
| Receivables | — | — | — | — | — | — | $29,276 | — |
| Inventory | $18.94M | $17.59M | $15.49M | $13.79M | $9.69M | $5.13M | $4.72M | $1.39M |
| Current assets | $110.85M | $110.15M | $54.04M | $73.11M | $82.23M | $90.35M | $53.48M | $64.47M |
| PP&E, net | $9.14M | $9.20M | $8.77M | $5.48M | $3.19M | $3.01M | $1.24M | $795,000 |
| Total assets | $147.19M | $138.68M | $80.29M | $97.23M | $104.99M | $114.93M | $75.50M | $73.56M |
| Current liabilities | $52.54M | $52.02M | $12.07M | $14.05M | $10.35M | $9.69M | $6.73M | $8.33M |
| Long-term debt | $41.80M | $41.80M | $41.80M | $41.80M | $41.80M | $41.80M | $41.81M | $41.84M |
| Total debt | $41.80M | $41.80M | $41.80M | $41.80M | $41.80M | $41.80M | $41.81M | $41.84M |
| Total liabilities | $70.33M | $69.82M | $70.75M | $71.64M | $66.34M | $65.23M | $60.94M | $49.20M |
| Shareholders' equity | $76.85M | $68.86M | $9.54M | $25.59M | $38.65M | $49.70M | $14.56M | $24.36M |
| Net debt | $27.82M | -$17.55M | $35.24M | $36.01M | $26.55M | -$5.80M | $30.31M | $34.92M |
| Shares outstanding | 84.55M | 75.33M | 45.06M | 45.03M | 449.89M | 449.55M | 372.90M | 371.08M |
| Cash flow statement | ||||||||
| Operating cash flow | -$17.25M | -$17.19M | -$20.25M | -$15.01M | -$13.14M | -$11.48M | -$13.56M | -$10.99M |
| Capital expenditure | $87,000 | $2.85M | $3.29M | $1.46M | $1.28M | $889,000 | $60,000 | $65,539 |
| Free cash flow | -$17.34M | -$20.05M | -$23.54M | -$16.47M | -$14.42M | -$12.37M | -$13.62M | -$11.05M |
| Investing cash flow | -$51.52M | -$6.18M | $20.88M | $8.12M | -$19.08M | $896,000 | $17.91M | -$21.17M |
| Financing cash flow | $23.38M | $76.19M | $132,000 | $57,311 | -$138,000 | $46.67M | $242,000 | $2.68M |
| Depreciation & amortization | $400,000 | $300,000 | $125,000 | $115,000 | $100,000 | $100,000 | $79,000 | $90,641 |
| Stock-based compensation | $1.00M | $936,000 | $907,000 | $912,864 | $929,000 | $704,000 | $505,000 | $486,253 |
Free plan shows the latest 8 periods; Pro shows all 15 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.